Is Oral Ketoconazole FDA Approved?
Yes, oral ketoconazole remains FDA approved, but with severe restrictions—it should only be used when other effective antifungal therapy is not available or tolerated, and is explicitly NOT approved for onychomycosis, cutaneous dermatophyte infections, or Candida infections due to serious hepatotoxicity risks including fatal outcomes. 1
Current FDA Status and Restrictions
The FDA has maintained approval for oral ketoconazole but imposed strict limitations in 2013. The drug carries a black box warning for serious hepatotoxicity, including cases requiring liver transplantation or resulting in death. 1 This represents a dramatic shift from its original broad approval in 1981 2.
Approved Indications (Highly Limited)
Oral ketoconazole is now approved ONLY for:
- Endemic mycoses where alternatives are not available or feasible
- Situations where potential benefits outweigh the substantial risks 1, 3
Explicitly NOT Approved For:
- Onychomycosis (nail infections)
- Cutaneous dermatophyte infections
- Candida infections of any type 1
This is critical because these were common historical uses that are now contraindicated.
Mandatory Safety Monitoring Requirements
The FDA label mandates specific protocols:
Baseline testing required:
- SGGT, alkaline phosphatase, ALT, AST, total bilirubin
- Prothrombin time and INR
- Viral hepatitis screening 1
During treatment:
- Weekly serum ALT monitoring for the entire treatment duration
- Interrupt treatment if ALT exceeds upper limit of normal or rises 30% above baseline
- Obtain full liver panel if abnormalities detected 1
Additional warnings:
- Advise complete alcohol avoidance
- Avoid other hepatotoxic drugs when possible
- Do not exceed 200-400 mg daily dose 1
Other Serious FDA-Mandated Warnings
Beyond hepatotoxicity, the label includes warnings for:
- QT prolongation: Contraindicated with dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, and ranolazine 1
- Adrenal insufficiency: At doses ≥400 mg daily; monitor adrenal function in at-risk patients 1
- Anaphylaxis: Reported after first dose 1
Clinical Context
The 2016 IDSA candidiasis guidelines notably do not include oral ketoconazole in any treatment algorithms, reflecting the medical community's abandonment of this agent for Candida infections 4. The guideline recommends fluconazole, echinocandins, or other azoles (itraconazole, posaconazole, voriconazole) instead.
Common pitfall: Clinicians may remember ketoconazole from earlier training as a first-line antifungal. This is outdated and dangerous. The drug has been withdrawn from European and Australian markets entirely 3.
Use in Research Settings
Interestingly, ketoconazole remains relatively safe as a CYP3A4 inhibitor in short-term drug interaction studies (median 6 days), with only 1.7% of research participants showing elevated transaminases and no deaths reported 5. This contrasts sharply with therapeutic use (median 276 days) where 5.6% developed elevated liver enzymes 5.
In summary: Oral ketoconazole is FDA approved but functionally obsolete for most clinical purposes, reserved only for rare endemic mycoses when no alternatives exist, and requires intensive hepatic monitoring that makes its use impractical in routine practice.